Consun Pharma (01681) has announced that on September 10, 2026, it expended approximately HK$3.999 million to buy back 305,000 of its own shares.

This share repurchase transaction reflects the company's ongoing capital management strategy, utilizing its financial resources to potentially enhance shareholder value. The buyback was executed through open market purchases, with the total consideration aligning with the company's disclosed budget for such activities.

The repurchase of shares by Consun Pharma is part of a broader trend among listed entities in the healthcare sector, which often deploy surplus cash to buy back stock when they perceive the market price to be undervalued. Following the transaction, the company's issued share capital will be adjusted accordingly, and further disclosures will be made if necessary under applicable listing rules.